Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Increases By 29,900.8%

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 3,625,291 shares, a growth of 29,900.8% from the December 15th total of 12,084 shares. Currently, 13.3% of the shares of the company are short sold. Based on an average trading volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days. Based on an average trading volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days. Currently, 13.3% of the shares of the company are short sold.

PicoCELA Stock Performance

Shares of PCLA traded down $0.02 during mid-day trading on Monday, reaching $0.25. The stock had a trading volume of 1,330,513 shares, compared to its average volume of 2,166,882. PicoCELA has a 12 month low of $0.12 and a 12 month high of $9.80. The business has a fifty day moving average of $0.29 and a 200 day moving average of $0.57.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PicoCELA in a report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to MarketBeat, PicoCELA has an average rating of “Sell”.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new position in PicoCELA Inc. (NASDAQ:PCLA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent SEC filing.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.